With the new classification of chronic myeloproliferative disorders, and the rise of interest in molecularly targeted therapies, this timely text brings together international experts on the topic to discuss the current technologies and their implications for the treatment of patients.
This title comprehensively covers chronic myeloid leukemia and Ph-negative chronic myeloproliferative disorders and is an essential resource for all practitioners in Hematologic Oncology.
Table of Contents
I. Bcr/Abl Positive Chronic Myeloproliferative Disorders. 1. Epidemiology and history. 2. Cytogenetics and molecular biology. 3. Risk stratification. 4. Clinical features. 5. Non-transplant treatment options. 6. Allogeneic stem cell transplantation. 7. Autologous stem cell transplantation. 8. Vaccines. 9. A therapeutic algorithm and concluding remarks. II. Bcr/Abl Negative Chronic Myeloproliferative Disorders. 10. Epidemiology and history. 11. Cytogenetics and molecular biology. 12. Risk stratification. 13. Clinical features. 14. Non-transplant treatment options. 15. Transplantation options. 16. A therapeutic algorithm and concluding remarks.
TARIQ I MUGHAL is Professor of Medicine and Haematology/Oncology at the University of Texas Southwestern Medical School, Dallas, USA and Consultant Haematologist at Guy’s & St Thomas’ Hospitals, London UK
JOHN M. GOLDMAN is Professor of Haematology at Imperial College London, Hammersmith Hospital, London, UK.